Patents Examined by Neil P Hammell
-
Patent number: 11293022Abstract: This invention pertains to single-stranded carrier nucleic acids and their methods of use for enhancing genome editing ribonucleoprotein complex transfection into cells and the resulting enhancement of CRISPR editing on the target DNA within those cells, as well as introduction of chemical modifications which reduce the integration of the single-stranded carrier nucleic acids at double-stranded breaks.Type: GrantFiled: December 12, 2017Date of Patent: April 5, 2022Assignee: Integrated DNA Technologies, Inc.Inventors: Rolf Turk, Mark A. Behlke, Chris Vinci
-
Patent number: 11286468Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.Type: GrantFiled: August 22, 2018Date of Patent: March 29, 2022Assignee: The General Hospital CorporationInventors: J. Keith Joung, Benjamin Kleinstiver
-
Patent number: 11279926Abstract: The present disclosure provides methods, kits, and compositions for generating DNA molecules encoding CRISPR/Cas guide RNAs (e.g., Cas9 single guide RNAs or Cas9 targeter RNAs). A library of such DNA molecules can be generated from any DNA source. The methods include a step of contacting target DNA with one or more DNA endonucleases that specifically bind to and cleave within a recognition sequence that includes a PAM sequence, to generate a plurality of cleavage fragments, to which a DNA adapter can be attached. A distal-cleaving DNA endonuclease can be used that specifically binds to a recognition sequence in the DNA adapter and cleaves at a site within the attached DNA cleavage fragments to generate a library of CRISPR/Cas guide sequences. After removal of all or a portion of the DNA adapter, a constant region of a guide RNA can be attached to generate DNA molecules encoding CRISPR/Cas guide RNAs.Type: GrantFiled: June 2, 2016Date of Patent: March 22, 2022Assignee: The Regents of the University of CaliforniaInventors: Andrew B. Lane, Rebecca Heald
-
Patent number: 11274318Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: May 21, 2021Date of Patent: March 15, 2022Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11274305Abstract: Methods and kits for excising HIV-1 DNA in vivo are provided, which employ Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-Associated (cas) proteins. Vectors harboring nucleic acids encoding one or more guide RNA, wherein said guide RNA hybridizes with a target HIV-1 DNA are also provided.Type: GrantFiled: March 25, 2014Date of Patent: March 15, 2022Assignees: TRUSTEES OF DARTMOUTH COLLEGE, United States Government as Represented by The Department of Veterans AffairsInventors: Alexandra L. Howell, Susan K. Eszterhas
-
Patent number: 11268082Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cpf1 or variants thereof, and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a napDNAbp (e.g., CasX, CasY, Cpf1, C2c1, C2c2, C2C3, and Argonaute) and nucleic acid editing proteins or domains, are provided.Type: GrantFiled: March 23, 2018Date of Patent: March 8, 2022Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, Alexis Christine Komor, Liwei Chen, Holly A. Rees
-
Patent number: 11261470Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti FcRn antibodies and proteins made by the methods described herein.Type: GrantFiled: April 23, 2018Date of Patent: March 1, 2022Assignee: UCB BIOPHARMA SRLInventors: Philip Jonathan Bassett, David Paul Humphreys, Pareshkumar Manjibhai Patel
-
Patent number: 11254918Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.Type: GrantFiled: November 6, 2020Date of Patent: February 22, 2022Assignees: The Board of Trustees of the Leland Stanford Junior University, Novome Biotechnolooies, Inc.Inventors: Justin L. Sonnenburg, Weston R. Whitaker, Elizabeth Stanley, William C. DeLoache
-
Patent number: 11254933Abstract: Methods, compositions, and kits are provided for CRISPR/Cas mediated transcriptional modulation.Type: GrantFiled: July 14, 2015Date of Patent: February 22, 2022Assignee: The Regents of the University of CaliforniaInventors: Luke A Gilbert, Max Horlbeck, Martin Kampmann, Lei S Qi, Jonathan S Weissman
-
Patent number: 11249084Abstract: This document relates to materials and methods involved in assessing inflammatory bowel disease patients at risk for developing cancer. For example, materials and methods for monitoring colorectal cancer risk in ulcerative colitis patients are provided.Type: GrantFiled: June 28, 2018Date of Patent: February 15, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: Megan Garrity-Park, Thomas C. Smyrk, Edward V. Loftus, Jr., William J. Sandborn
-
Patent number: 11242543Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: October 23, 2020Date of Patent: February 8, 2022Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11208638Abstract: The present disclosure provides a Cas9 heterodimer, as well as nucleic acids encoding the Cas9 heterodimer, and host cells comprising the nucleic acids. The present disclosure provides a system that includes a Cas9 heterodimer of the present disclosure and at least one of: a Cas9 guide RNA, and a dimerizing agent. A Cas9 heterodimer of the present disclosure is useful in a wide variety of applications, which are also provided.Type: GrantFiled: January 7, 2016Date of Patent: December 28, 2021Assignee: The Regents of the University of CaliforniaInventors: Samuel H. Sternberg, Jennifer A. Doudna, Addison V. Wright
-
Patent number: 11203759Abstract: The invention provided herein relates to sequence determinants that elicit certain levels of gene expression and methods for obtaining engineered ligand-responsive gene switches comprising these sequence determinants. More particularly, the invention provided herein relates to molecular building blocks (i.e., discrete nucleotide sequences), synthetic ligand-responsive gene switches comprising an assembly of these molecular building blocks, and methods of using synthetic ligand-responsive gene switches as customizable and controllable expression systems and sensors.Type: GrantFiled: September 7, 2017Date of Patent: December 21, 2021Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Patricia J. Kiley, Dan M. Park
-
Patent number: 11203620Abstract: The present invention provides a modified eukaryotic cell wherein the modified eukaryotic cell is not able to provide an SSN6-like protein that exerts its wildtype function and/or wildtype activity, the amount of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like protein being present in its wildtype form, and/or essentially no SSN6-like protein is present in the modified cell. Additionally, the present invention provides a polynucleotide sequence comprising a modified ssn6-like gene, and a vector comprising said polynucleoptide. Additionally provided is an expression vector comprising a promoter that is repressed in the presence of SSN6-like protein, and a host cell comprising said vectors. The present invention further refers to a method for determining the purity of a composition by using the modified eukaryotic cell, to a method of expressing gene(s) of interest, and eukaryotic cells comprising modified ssn6-like gene.Type: GrantFiled: March 2, 2016Date of Patent: December 21, 2021Assignee: Novartis AGInventors: Clemens Achmüller, Ferdinand Zepeck, Franz Hartner, Thomas Specht
-
Patent number: 11198879Abstract: The present invention provides novel reagents and a cloning procedure based on homologous recombination for the site-directed cloning of a DNA fragment to a vector at designed site(s). The cloning reagents are made of mixture of extracts from at least two different cell types, preferably a mixture made of extracts from wild-type E. coli and S. cerevisiae. Due to the activity of the mixture of cell extracts, recombination occurs between the 3? and 5?-ends of the target DNA and at the ends of linearized vector, which facilitates in-frame construction of expression vectors.Type: GrantFiled: October 25, 2018Date of Patent: December 14, 2021Assignee: VIET NAM NATIONAL UNIVERSITY HO CHI MINH CITYInventors: Phuong Thao Thi Dang, My Trinh Thi Nguyen, Nghia Hieu Nguyen, Thuoc Linh Tran
-
Patent number: 11186849Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: October 29, 2020Date of Patent: November 30, 2021Assignees: The Regents of the University of California, University of Vienna, Emmanuelle CharpentierInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11186817Abstract: The present invention relates to an optimal medium for growing a cell line auxotrophic for tetrahydrofolate (THF) and producing a desired material in the cell with high efficiency. In particular, the present invention provides a method for enhancing cell growth by adding tetrahydrofolate (THF), or a precursor or derivative thereof into a chemical composition cell medium.Type: GrantFiled: February 23, 2015Date of Patent: November 30, 2021Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Hong-Woo Park, Bong Gyun Kim
-
MYO1A for predicting conversion of acute pain into chronic pain and use of MYO1A for therapy of pain
Patent number: 11180791Abstract: Products and methods for assessing the predisposition of a subject to develop an injury-induced chronic mechanical pain and/or an inflammatory-induced chronic thermal pain are provided. More specifically, methods for the assessment of the predisposition of a subject to develop an injury-induced chronic mechanical pain and/or an inflammatory-induced chronic thermal pain using the MYO1A gene as a biomarker and methods of treating selected subjects are provided.Type: GrantFiled: March 7, 2017Date of Patent: November 23, 2021Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Abdelaziz Moqrich -
Patent number: 11180792Abstract: The present disclosure provides compositions and methods for labeling a single stranded target nucleic acid. Subject compositions include a Cas9 protein, a Cas9 guide RNA, and a quenched PAMmer. A subject quenched PAMmer is a single stranded oligonucleotide having (i) a protospacer adjacent motif (PAM) sequence; (ii) a detectable label; (iii) a quencher moiety that quenches the detectable label; and (iv) at least one of: a specificity segment positioned 5? of the PAM sequence, and an orientation segment positioned 3? of the PAM sequence. In the subject methods, the Cas9 protein cleaves the quenched PAMmer at a cleavage site positioned between the detectable label and the quencher moiety to produce: (a) a first cleavage product that is hybridized with the target nucleic acid and comprises the detectable label; and (b) a second cleavage product that is not hybridized with the target nucleic acid and comprises the quencher moiety.Type: GrantFiled: January 27, 2016Date of Patent: November 23, 2021Assignee: The Regents of the University of CaliforniaInventors: Mitchell R. O'Connell, Jennifer A. Doudna
-
Patent number: 11180743Abstract: Provided are compositions and methods that include one or more of: (1) a “CasZ” protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a “CasZ trancRNA”), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).Type: GrantFiled: February 12, 2020Date of Patent: November 23, 2021Assignee: The Regents of the University of CaliforniaInventors: Jennifer A. Doudna, David Burstein, Janice S. Chen, Lucas B. Harrington, David Paez-Espino, Jillian F. Banfield